1. Lassmann, H . Mechanisms of white matter damage in multiple sclerosis. Glia 2014; 62: 1816–1830. 2014/01/29.
Google Scholar | Crossref | Medline | ISI2. Michel, L, Touil, H, Pikor, NB, et al. B cells in the multiple sclerosis central nervous system: trafficking and contribution to CNS-compartmentalized inflammation. Front Immunol 2015; 6: 636. 2016. /01/07.
Google Scholar | Crossref | Medline | ISI3. Prinz, M, Priller, J, Sisodia, SS, et al. Heterogeneity of CNS myeloid cells and their roles in neurodegeneration. Nat Neurosci 2011; 14: 1227–1235. 2011/09/29.
Google Scholar | Crossref | Medline | ISI4. Polman, CH, O'Connor, PW, Havrdova, E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899–910. Clinical Trial, Phase III Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't 2006/03/03.
Google Scholar | Crossref | Medline | ISI5. Yednock, TA, Cannon, C, Fritz, LC, et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992; 356: 63–66. 1992/03/05.
Google Scholar | Crossref | Medline | ISI6. Bloomgren, G, Richman, S, Hotermans, C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012; 366: 1870–1880. 2012/05/18.
Google Scholar | Crossref | Medline | ISI7. Tysabri (natalizumab) injection, for intravenious use [package insert]. Cambridge, MA 2018.
Google Scholar8. Berger, JR, Cree, BA, Greenberg, B, et al. Progressive multifocal leukoencephalopathy after fingolimod treatment. Neurology 2018; 90: e1815–e1821. 2018/04/20.
Google Scholar | Crossref | Medline9. Berger, JR, Malik, V, Lacey, S, et al. Correction to: progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event. J Neurovirol 2018; 24: 332. 2018/04/11.
Google Scholar | Crossref | Medline10. Dammeier, N, Schubert, V, Hauser, TK, et al. Case report of a patient with progressive multifocal leukoencephalopathy under treatment with dimethyl fumarate. BMC Neurol 2015; 15: 108. 2015/07/15.
Google Scholar | Crossref | Medline11. van Oosten, BW, Killestein, J, Barkhof, F, et al. PML In a patient treated with dimethyl fumarate from a compounding pharmacy. N Engl J Med 2013; 368: 1658–1659. 2013/04/26.
Google Scholar | Crossref | Medline | ISI12. Jordan, AL, Yang, J, Fisher, CJ, et al. Progressive multifocal leukoencephalopathy in dimethyl fumarate-treated multiple sclerosis patients. Mult Scler 2020 Aug 18: 1352458520949158. 10.1177/1352458520949158
Google Scholar | SAGE Journals13. Lorefice, L, Fenu, G, Gerevini, S, et al. PML In a person with multiple sclerosis: is teriflunomide the felon? Neurology 2018; 90: 83–85. 2017/12/08.
Google Scholar | Crossref | Medline14. West, TW, Cree, BA. Natalizumab dosage suspension: are we helping or hurting? Ann Neurol 2010; 68: 395–399.
Google Scholar | Crossref | Medline | ISI15. Hoepner, R, Havla, J, Eienbröker, C, et al. Predictors for multiple sclerosis relapses after switching from natalizumab to fingolimod. Mult Scler 2014; 20: 1714–1720. 2014/05/21.
Google Scholar | SAGE Journals | ISI16. Fox, RJ, Cree, BA, De Sèze, J, et al. MS Disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. Neurology 2014; 82: 1491–1498. 2014/04/01.
Google Scholar | Crossref | Medline | ISI17. Leurs, CE, van Kempen, ZL, Dekker, I, et al. Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients. Mult Scler 2018; 24: 1453–1460. 2017/08/22.
Google Scholar | SAGE Journals | ISI18. Rinaldi, F, Seppi, D, Calabrese, M, et al. Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: clinical and magnetic resonance imaging findings. Mult Scler 2012; 18: 1640–1643. 2012/10/27.
Google Scholar | SAGE Journals | ISI19. Larochelle, C, Metz, I, Lécuyer, MA, et al. Immunological and pathological characterization of fatal rebound MS activity following natalizumab withdrawal. Mult Scler 2017; 23: 72–81. 2016/04/03.
Google Scholar | SAGE Journals | ISI20. Rigau, V, Mania, A, Béfort, P, et al. Lethal multiple sclerosis relapse after natalizumab withdrawal. Neurology 2012; 79: 2214–2216. 2012/10/27.
Google Scholar | Crossref | Medline | ISI21. Cohan, SL, Moses, H, Calkwood, J, et al. Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: a multicenter retrospective observational study (STRATEGY). Mult Scler Relat Disord 2018; 22: 27–34.
Google Scholar | Crossref | Medline22. Naegelin, Y, Rasenack, M, Andelova, M, et al. Shortening the washout to 4 weeks when switching from natalizumab to fingolimod and risk of disease reactivation in multiple sclerosis. Mult Scler Relat Disord 2018; 25: 14–20. 2018/07/18.
Google Scholar | Crossref | Medline23. Iaffaldano, P, Lucisano, G, Pozzilli, C, et al. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis. Brain : a journal of neurology 2015; 138: 3275–3286. 2015/09/13.
Google Scholar | Crossref | Medline | ISI24. Alping, P, Frisell, T, Novakova, L, et al. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Ann Neurol 2016; 79: 950–958. 2016/04/03.
Google Scholar | Crossref | Medline | ISI25. Pfeuffer, S, Schmidt, R, Straeten, FA, et al. Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation. J Neurol 2019; 266: 165–173. 2018/11/18.
Google Scholar | Crossref | Medline26. AUBAGIO® (teriflunomide) tablets [package insert]. Cambridge, MA 02142: Genzyme Corporation, A SANOFI COMPANY, 2020.
Google Scholar27. Confavreux, C, O'Connor, P, Comi, G, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 2014; 13: 247–256. 2014/01/28.
Google Scholar | Crossref | Medline | ISI28. O'Connor, P, Wolinsky, JS, Confavreux, C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011; 365: 1293–1303. Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't 2011/10/14.
Google Scholar | Crossref | Medline | ISI29. Wolinsky, JS, Dukovic, D, Truffinet, P, et al. The efficacy of teriflunomide is evident before steady-state plasma concentrations are reached. Poster Presented at Joint ACTRIMS-ECTRIMS Meeting Boston, MA, USA2014.
Google Scholar30. Cohan, SL, Edwards, K, Lucas, L, et al. Reducing return of disease activity in patients with relapsing multiple sclerosis transitioned from natalizumab to teriflunomide: 12-month interim results of teriflunomide therapy. Mult Scler J Exp Transl Clin 2019; 5: 2055217318824618.
Google Scholar | SAGE Journals31. Kappos, L . Neurostatus scoring. Slightly modified from J.F. Kurtzke. Neurology 1983; 33: 1444–1452. (2011).
Google Scholar | Medline32. Plavina, T, Muralidharan, KK, Kuesters, G, et al. Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients. Neurology 2017; 89: 1584–1593. 2017/09/17.
Google Scholar | Crossref | Medline33. O'Connor, PW, Goodman, A, Kappos, L, et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology 2011; 76: 1858–1865. 2011/05/06.
Google Scholar | Crossref | Medline | ISI34. Miller, DH, Khan, OA, Sheremata, WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003; 348: 15–23. 2003/01/03.
Google Scholar | Crossref | Medline | ISI35. Krumbholz, M, Meinl, I, Kümpfel, T, et al. Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. Neurology 2008; 71: 1350–1354. 2008/10/22.
Google Scholar | Crossref | Medline | ISI36. Frisullo, G, Iorio, R, Plantone, D, et al. CD4+T-bet+, CD4+pSTAT3+ and CD8+T-bet+ T cells accumulate in peripheral blood during NZB treatment. Mult Scler 2011; 17: 556–566. 2010/12/24.
Google Scholar | SAGE Journals | ISI37. Stüve, O, Cravens, PD, Frohman, EM, et al. Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. Neurology 2009; 72: 396–401. 2008/11/07.
Google Scholar | Crossref | Medline | ISI38. Jing, D, Oelschlaegel, U, Ordemann, R, et al. CD49d Blockade by natalizumab in patients with multiple sclerosis affects steady-state hematopoiesis and mobilizes progenitors with a distinct phenotype and function. Bone Marrow Transplant 2010; 45: 1489–1496. 2010/01/26.
Google Scholar | Crossref | Medline | ISI39. Cofield, SS, Fox, RJ, Tyry, T, et al. Disability progression after switching from natalizumab to fingolimod or interferon Beta/Glatiramer Acetate Therapies: a NARCOMS analysis. Int J MS Care 2016; 18: 230–238. 2016/11/03.
Google Scholar | Crossref | Medline